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Abstract
Folate-sensitive fragile sites (FSFS) are a rare cytogenetically visible subset of dynamic mutations. Of the eight molecularly
characterized FSFS, four are associated with intellectual disability (ID). Cytogenetic expression results from CGG tri-
nucleotide-repeat expansion mutation associated with local CpG hypermethylation and transcriptional silencing. The best
studied is the FRAXA site in the FMR1 gene, where large expansions cause fragile X syndrome, the most common inherited
ID syndrome. Here we studied three families with FRA2A expression at 2q11 associated with a wide spectrum of
neurodevelopmental phenotypes. We identified a polymorphic CGG repeat in a conserved, brain-active alternative
promoter of the AFF3 gene, an autosomal homolog of the X-linked AFF2/FMR2 gene: Expansion of the AFF2 CGG repeat
causes FRAXE ID. We found that FRA2A-expressing individuals have mosaic expansions of the AFF3 CGG repeat in the range
of several hundred repeat units. Moreover, bisulfite sequencing and pyrosequencing both suggest AFF3 promoter
hypermethylation. cSNP-analysis demonstrates monoallelic expression of the AFF3 gene in FRA2A carriers thus predicting
that FRA2A expression results in functional haploinsufficiency for AFF3 at least in a subset of tissues. By whole-mount in situ
hybridization the mouse AFF3 ortholog shows strong regional expression in the developing brain, somites and limb buds in
9.5–12.5dpc mouse embryos. Our data suggest that there may be an association between FRA2A and a delay in the
acquisition of motor and language skills in the families studied here. However, additional cases are required to firmly
establish a causal relationship.
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Introduction
Dynamic mutations are heritable unstable expansions of short,
genomic repeat sequences. Various pathogenic mechanisms have
been associated with dynamic mutations [1,2] and at least 40
neurological, neurodegenerative and neuromuscular disorders are
known to be caused by these types of mutations [3,4]. Expansions
of these unstable sequences may occur in promoters, coding
regions, introns and 39 and 59 untranslated regions (UTR) of genes
[5,6,7]. Known and putative disease mechanisms include aberrant
splicing [8], loss or gain of function of the encoded protein [9,10],
the expanded repeat itself [11] or its RNA transcript [12,13] and
Repeat Associated Non-ATG translation (RAN translation)
[14,15]. The size threshold at which a repeat becomes unstable
and/or pathogenic varies widely, from the expansion of only a few
trinucleotide repeats in e.g. ARX-associated infantile epileptic
encephalopathy (MIM 308350) to over a thousand repeats in e.g.
DMPK-associated myotonic dystrophy (MIM 160900), FXN-
associated Friedreich ataxia (MIM 229300) and FMR1-associated
fragile X syndrome (MIM 300624) [16,17,18].
Fragile sites represent a specific subset of dynamic mutations
that are visible as gaps or breaks on metaphase chromosomes from
cells cultured under specific conditions. Fragile sites are catego-
rised by the nature of the inducing culture condition and the
population frequency of the mutation [19]. FRAXA is a rare,
folate sensitive fragile site (FSFS) associated with a trinucleotide
repeat (CGG) expansion mutation in the 59 UTR of the FMR1
gene resulting in fragile X syndrome, the most common inherited
intellectual disability syndrome [20]. Twenty-six other FSFS have
been reported cytogenetically but only eight of these have been
molecularly characterized: FRAXA [20], FRAXE [21], FRAXF
[22], FRA16A [23], FRA11B [24], FRA10A [25], FRA12A [26]
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and FRA11A [27]. To date, all characterized FSFS are due to a
CCG/CGG trinucleotide repeat expansion. The expanded repeat
and any adjacent CpG island become hypermethylated and
transcriptionally silenced at a locus-specific repeat size-threshold
[28]. At least four of the eight characterized rare, folate sensitive
fragile sites are associated with a neurodevelopmental disorder.
The relevance of folate sensitive fragile sites to intellectual
disability (ID) is strengthened by five independent population
studies that have all shown that autosomal folate sensitive fragile
sites are overrepresented in people with ID compared to control
groups without ID, with a prevalence of 1.2% and 0.27%
respectively [reviewed in 29]. It thus seems likely that as yet
uncharacterized CGG/CCG repeat expansions may be associated
with neurodevelopmental problems.
An autosomal FSFS on chromosomal band 2q11.2-q12 has
been previously described [30,31,32]. We studied three families
with FRA2A-expression and a wide spectrum of neurodevelop-
mental and other anomalies. We identified expansion of an
intronic CGG repeat leading to hypermethylation of at least one
promoter of the AFF3 gene in all FRA2A carriers and we
hypothesise that the associated transcriptional silencing of AFF3 in
the brain may be responsible for some of the developmental
features observed in FRA2A carriers.
Results
FRA2A is due to expansion of a polymorphic CGG repeat
within AFF3
Using the simple repeat track on UCSC genome browser
(GRCh37/hg19) we identified three candidate CGG repeats in the
FRA2A containing region (2q11-12). One of these repeats is
located within the LAF4/AFF3 gene (chr2:100721261–100721286;
hg19), an autosomal homolog of the FRAXE-associated FMR2/
AFF2 gene. In order to determine whether this CGG-repeat is
expanded in FRA2A we used metaphase FISH analysis on a
FRA2A-expressing individual (Figure 1; AII.3) with the BAC clone
RP11-549H5 (chr2:100,588,792–100,759,365; hg19) encompass-
ing the repeat. The FISH signal spanned the FRA2A fragile site
(Figure 2A). Consistent with this the FISH signals from probes
RP11-436F6 (AC010736) and RP11-506F3 (AC074387) were
centromeric and telomeric to FRA2A, respectively. To establish
co-location of the CGG repeat with the fragile site, long-range
PCR-generated probes L10K (chr2:100721983–100733233; hg19)
and L18K (chr2:100700447–100718834; hg19) were targeted to
the genomic regions on either side of the (CGG)n repeat. These
probes did indeed flank the fragile site, locating FRA2A to a 3.1 kb
interval within the AFF3 gene (Figure 2B). The second red (L18K)
FISH signal observed at 2q13 (Figure 2B) is the result of two copies
of a 24 kb low copy repeat flanking the NPHP1 gene (Figure 2C)
(chr2: 110520380–110538822 and chr2:111347822–111366260;
Figure 1. Description of FRA2A Families A–C. Females are represented by circles, males by squares. The percentage of cells showing FRA2A
expression are indicated on the bottom right-hand side of the symbol. As discussed in the text the 4% FRA2A expression seen in individual AI.1
represents a false positive. The case number used to indicate the FRA2A carriers in the text is given on the top left-hand side of the symbol. N within a
symbol indicated individuals expression of the fragile site was not examined or observed. The associated phenotypes in individuals AII.3, AII.4, BII.1
and CII.1 are detailed in the boxed symbol key. The proband in each family is arrowed.
doi:10.1371/journal.pgen.1004242.g001
Author Summary
Some human genetic diseases are caused by dynamic
mutations, or expansions of a short repeated sequence in
the genome that can be unstably passed on from
generation to generation. A subset of these dynamic
mutations known as fragile sites can be seen as a break or
gap on the chromosome when cells are cultured under
specific conditions. To date eight folate-sensitive fragile
sites (FSFS) have been characterized, and all are due to
CGG-repeat expansions within the 59 UTR or promoter
region of the respective gene. When the repeat expands in
size, it becomes hypermethylated and the adjacent gene
or genes are transcriptionally silenced. For at least four of
the eight known fragile sites this silencing of the
associated gene(s) lead to intellectual disability syndromes
such as fragile X. In this work we describe molecular
characterization of an autosomal FSFS called FRA2A on
chromosome 2. As the molecular cause of FRA2A, we
identify an expansion of a CGG repeat which subsequently
results in silencing of the neighbouring gene AFF3. This
gene is one of the four autosomal paralogss of the AFF2/
FMR2 gene which, when mutated, is the cause of the
FRAXE syndrome. We find that FRA2A expression is
associated with highly variable developmental anomalies
in the three FRA2A families studied.
AFF3 Silencing in FRA2A
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hg19). A copy of this sequence is also located adjacent to the
CGG-repeat within the AFF3 gene in the region covered by L18K.
PCR-based amplification and sequencing of the AFF3 CGG
repeat in 200 control chromosomes revealed it to be highly
polymorphic with a length ranging from 3 to 20 copies (Figure 3).
The most frequent CGG allele contains eight repeats (as does the
genomic reference sequence; chr2:100721261–100721286; hg19).
To exclude the possibility that apparently homozygous control
individuals are in fact heterozygous for the detected allele in
combination with a large expansion that is not detected by this
protocol, we amplified these samples with gene specific repeat
primed PCR (Asuragen Inc., Austin Texas, USA). This protocol
enables us to detect expansions up to 300–500 repeats. However,
no expanded repeats were detected in control chromosomes, and
the genotype distribution agreed with Hardy-Weinberg equilibri-
um (P.0.05).
PCR amplification of the repeat in the FRA2A-expressing
individuals from AI.1, AII.3, AII.4, AIII.1, BII.1 and CII.1
(Figure 1) showed a single CGG allele in the normal size range. An
additional smaller fragment was detected in subject AII.4.
Sequence analysis of the smaller PCR product showed a 134-bp
deletion encompassing the entire CGG repeat as well as some
flanking sequences (Figure S1). This deletion was not detected in
800 control chromosomes. To visualize the repeat expansion in
the FRA2A-positive individuals, we performed Southern blotting
on HindIII digested genomic DNA of all available members of the
three families (AI.1, AII.3, AII.4, AIII.1, BI.2, BII.1, CI.1, CI.2
and CII.1) and control samples. A 4.4 kb fragment was observed
in all cases and controls. In five affected FRA2A-positive
individuals we detected additional large fragments or smears
compatible with the presence of an expanded allele (Figure 4).
Two FRA2A-negative parents of FRA2A-positive individuals (BI.2
and CI.2) showed additional larger fragments indicative of repeat
expansion. No evidence of an expanded fragment was observed in
the control samples or in FRA2A-negative individual CI.1.
Interestingly, individual AI.1 who had been reported as showing
a low level of FRA2A-positive cells showed no fragments
suggestive of an expansion mutation. A Southern blot of the same
samples after NcoI digestion gave very similar results (data not
shown).
A gene specific repeat-primed PCR assay was used for accurate
sizing of the repeat expansion mutations. The mothers in family B
and C both showed a slightly expanded allele (6120 and 106
repeat units, respectively) in addition to an allele in the normal size
range (15 and 17 repeat units, respectively) while their offspring
show one allele of 8 units compatible with paternal inheritance
and one allele with a large expansion of more than 300 units
(Figure S2). This strongly suggests that the expanded allele in both
families was inherited from the mother (Table 1). In family A, the
apparently FRA2A-positive individual AI.1 showed no evidence of
an expanded allele on either Southern blot analysis or on repeat
primed PCR. This apparent discrepancy could be resolved
Figure 2. FISH analysis of the FRA2A fragile site. A. The BAC-clone 549H5 (labelled green) spans the fragile site FRA2A. B. FISH analysis using
the 10 kb L10K (labelled green; chr2: 100721983–100733233; hg19) and 18 kb L18K (labelled red; chr2: 100700447–100718834; hg19) PCR-generated
probes, targeted to map either side of FRA2A. The additional telomeric FISH signal on the red channel (red arrow chr2: 110520380–110538822 and
chr2:111347822–111366260; hg19) is the result of a 24 kb low copy repeat (24 kb LCR pink text) encompassing L18K. C. A schematic representation
of the position of the LCR.
doi:10.1371/journal.pgen.1004242.g002
AFF3 Silencing in FRA2A
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genetically using the microsatellite markers (D2S2209/AF-
MA246XE9 and D2S2311/AFMB355ZG1, Figure S3). The
FRA2A-positive daughters of AI.1, AII.3 and AII.4, were shown
to have inherited a different non-expanded allele (8 CGG units)
from him, while they share a common allele with the mother
(AI.2). Their FRA2A-positive grand-daughter, AIII.1 also inher-
ited this maternal allele. The expansion was therefore probably
inherited from AI.2, with the 4% FRA2A expression in AI.1
representing a false-positive cytogenetic result. Unfortunately
DNA was not available from AI.2 to determine if she also carried
an intermediately expanded allele.
Characterization of the two major AFF3 transcriptional
start sites (TSS)
The RefSeq AFF3 gene model consists of 23 coding exons and
two 59 non-coding exons together spanning 558 kb genomic DNA
[33]. Here, the 59 non-coding exons are named exons 1 and 2 with
the first coding exon called exon 3. An AFF3-specific cDNA probe
encompassing the final 5 exons was used for northern blot analysis.
A major transcript of approximately 8 kb, corresponding to the
predicted size was detected in several tissues, including brain,
placenta and lung (data not shown).
To determine the precise location of the AFF3 transcriptional
start sites (TSSs) in relation to the expanded repeat we used Cap
Analysis of Gene Expression (CAGE) data from the FANTOM4
consortium. FANTOM4 produces sequence tags from the 59 end
of mRNAs from many different tissue sources and species and
maps these to the reference genome [34]. Mapped CAGE tags
reveal the sites of transcription initiation at single nucleotide
resolution and provides a semi-quantitative measure of steady state
mRNA levels for those transcripts using a tags per million (TPM)
metric. The TPM scores for three different human tissue groups
(brain, immune and other tissues) are plotted in Figure 5B. AFF3 is
transcribed in telomeric to centromeric orientation and the x axis
of these graphs represent the hg19 genomic coordinates. The
location of the 25 annotated exons of the RefSeq model of the
AFF3 gene (NM_001025108) is represented above the graphs
using the same genomic coordinates. To assess the transcriptional
activity of AFF3 during early brain development we mapped
transcriptome sequencing reads of mRNA (RNA-seq) from three
different human fetal brain samples to the regions surrounding the
TSS identified by CAGE (Figure 5C).
CAGE tag sequencing demonstrates two robust TSSs. The most
59 TSS corresponds to the 59 end of exon 1 at position
chr2:100759169 (GRCh37/hg19). This TSS is highly expressed
in immune tissues with a mean of 300 tags per million shown by
the blue bar in the middle graph (Figure 5B). There is no obvious
transcription of exon 1 on RNA-seq from human fetal brain
(Figure 5C, left-hand side). A second robust TSS was identified in
CAGE data from brain and other tissues which mapped within
intron 2 as shown by the blue bars in the top and bottom graphs in
Figure 5B. The highest levels are seen in the brain (mean of 60 tags
per million). An expanded representation of this region is shown in
the right-hand side of Figure 5C. This shows no evidence of
transcription of exon 2 but strong expression in exon 3. This also
shows evidence of an alternative exon 1 immediately 39 to the TSS
(Figure 5C, right hand side, black arrow). The TSS lies
immediately downstream of the CGG repeat (Figure 5D) suggest-
ing this expansion prone repeat is located within the core of an
alternate AFF3 promoter.
Figure 3. Allele frequencies of the FRA2A associated CGG repeat in a population of 100 control individuals. PCR amplification of the
repeat and subsequent sequencing in 200 control chromosomes revealed that it is highly polymorphic with a length ranging from 3 to 20 copies. The
most commonly found allele contains eight repeated units.
doi:10.1371/journal.pgen.1004242.g003
AFF3 Silencing in FRA2A
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The location and tissue specific activity of the AFF3
promoters are similar in mouse Aff3
FANTOM4 CAGE data also encompasses a range of mouse
tissues. From this we can demonstrate that both the exon 1 TSS
and intron 2 TSS are evolutionarily conserved and functional
TSSs. Although the CGG repeat itself is not conserved, a region of
low compositional complexity flanked by highly constrained non-
coding sequences is a conserved feature of the intron 2 TSS
promoter (Figure 5).
Whole mount in situ hybridization (WISH) using riboprobes
targeted to the 39UTR of Aff3 was used to determine the
developmental expression pattern in mouse embryos at 9.5, 10.5,
11.5 and 12.5 days post coitus (dpc). This has shown site and stage
specific expression of Aff3. The most striking areas of expression
are in the somites, the upper limb buds, the diencephalon/
prosomere I and the fusing primary palate (Figure 6).
AFF3 promoter regions are hypermethylated in
individuals with the FRA2A CGG-repeat expansion
In all rare, folate-sensitive sites characterised to date, CGG
repeat expansions are associated with hypermethylation of the
surrounding CpG island. Bisulfite sequencing indicated hyper-
methylation of the CpG island in all five affected FRA2A carriers
AII.3, AII.4, AIII.1, BII.1 and CII.1, while in healthy control
individuals this region was not methylated (figure S4). In order to
quantify the methylation level, we subsequently subjected all
samples to pyrosequencing. This technique allows accurate
quantification of methylation across individual CpG sites [35]. A
methylation frequency of 50% would be consistent with complete
methylation of the expanded allele as all affected individuals in this
study are heterozygous. We analyzed a short region of genomic
DNA (chr2:100721843–100721885; hg19) adjacent to the CGG
repeat in all available family members, containing four analysable
CpG dinucleotides (Figure S1 and Table 2). Methylation
percentages are congruous across the 4 CpG-sites in each
individual (p-values ranging from 0.417 to 1.000) and are
consistent with hypermethylation of the CGG repeat region in
individuals carrying an expanded allele. There is some suggestion
that the methylation frequency may be increasing upon genera-
tional transmission.
To exclude a non-specific effect of increasing age on the
methylation of this region, we pyrosequenced 72 individuals from
24 unrelated two-generation families. The ages within this control
group varied between 0 and 11 years for the children and between
23 and 53 years for the parents, which is comparable to the age
distribution in our FRA2A families at the time of DNA collection.
No methylation above the threshold was detected in any control
individual (data not shown). In the FRA2A-carriers the methyl-
ation level for each of the four CpG sites differed significantly from
the level determined in this control population (p-values#0.001 for
CpG site 1,2 and 4 and p,0.004 for CpG site 3), suggesting that
expansion of the repeat is associated with hypermethylation of the
region surrounding the repeat.
In AII.4, mosaic for a CGG-repeat expansion and a deletion,
the promoter region on the expanded allele was hypermethylated
as determined by bisulfite sequencing. The allele with the 134-bp
deletion was not methylated, as determined by Southern blotting
after double digestion with BamHI and NotI (data not shown).
Figure 4. Southern blot analysis of the AFF3 CGG repeat in all available members of the three families and two unrelated control
individuals (C). DNA restriction fragments obtained from blood samples of all available members of family A (lanes 1–4), B (lanes 5–6) and C (lanes
7–9) where blotted with a specific 32P-labeled probe (chr2:100088460–100089451; hg19) after digestion with HindIII. Lanes 10 and 11 contain DNA
restriction fragments from two unrelated control samples (represented as diamonds) after digestion with HindIII. In addition to a normal size allele
fragment of 4.4 kb, individuals CII.1, CI.2, BII.1, BI.2, AII.4, AII.3 and AIII.1 show additional fragments of a larger size, indicating repeat expansion. These
expanded fragments were not present in the controls and individuals CI.1 and AI.1. A 1 kb length marker is presented at the left of the figure.
doi:10.1371/journal.pgen.1004242.g004
AFF3 Silencing in FRA2A
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Monoallelic expression of the AFF3 gene in FRA2A
carriers
The level of AFF3 expression in lymphoblastoid cell lines is too
low to be reliably measured by RT-qPCR. To determine if
FRA2A results in transcriptional silencing of AFF3 in cis, we
utilized single nucleotide polymorphisms (SNP) mapping within
the open reading frame. Two such SNPs were found to be
heterozygous in the genomic DNA of affected FRA2A carrier
BII.1. Rs4851214 maps to exon 14 and heterozygous individuals
display both an T and a C peak (c.1499T/C) on Sanger
sequencing, while rs13427251 maps to exon 25 and heterozygotes
for this SNP show both an A and a T peak (c.5475A/T).
Sequencing cDNA from BII.1, revealed only a C peak at
rs4851214 (Figure 7) and only the A allele peak was seen for
rs13427251. These results are consistent with monoallelic
expression of AFF3 in this individual. Genomic DNA from
BII.1’s mother (BI.2) is homozygous for the rs13427251 T allele
(g.5475T/T) indicating that it is the maternal T allele carrying
the CGG expansion that is silenced in BII.1. cDNA of BI.2
showed a heterozygous signal for rs4851214 (c.1499T/C)
indicating that both AFF3 alleles are transcribed in the mother
despite partial methylation of her expanded allele.
Analysis of clinical phenotypes associated with FRA2A
Six FRA2A carriers were initially included in this study
(Figure 1, Table 3), four in Family A and one each in Families
B and C. Individual AIII.1 is currently too young to make any
conclusion about cognitive development. Individual A1.1 has no
discernible affected phenotype and he also has the lowest
expression of the fragile site. The molecular analysis presented
above strongly suggests that the 4% apparent expression of this
case represents a false positive and so was excluded from the
clinical analysis. Two FRA2A carriers AII.3 and AII.4 are adults;
both had global delay in their neurocognitive development to a
level that merited genetic investigations during childhood and
their long-term placement in special educational facilities.
However, as adults both of these individuals are functioning at a
normal level and are in full time employment. This raises the
possibility that they had a true delay in development rather than a
fixed disability. Something similar is observed in FRAXE patients
as most adult FRAXE males adapt to live a normal life. Individual
CII.1 was born prematurely and had significant respiratory
distress, which confounds the unambiguous interpretation of the
cause of her mild developmental delay. BII.1 has the most
significant delay, currently without a plausible non-genetic
explanation. Thus all four of the characterized true FRA2A
carriers did have significant delay in their motor and language
development.
To determine whether the FRA2A carriers with neurodevelop-
mental anomalies had additional mutations in the protein coding
region of the AFF3 gene, mutation analysis of all coding exons was
performed. No sequence abnormalities were detected in any of the
affected FRA2A carriers, except in subject AII.4, in which a 6-bp
deletion was identified in exon 14, removing two amino acids:
Threonine and Alanine (position 619 and 621 respectively)
(Figure 5A). Both amino acids are found in a region, enriched
with proline, serine and glutamic acid residues and located
between the transactivation domain and the nuclear localisation
signal (NLS). According to different prediction software (muta-
tiontaster, mutation assessor, Indelz), the deletion is benign.
Moreover, this 6-bp in-frame deletion was also present in the
unaffected father (AI.1).
Discussion
We provide compelling evidence that the molecular basis of the
FSFS FRA2A is a CGG repeat expansion in an alternative
promoter which is active in the brain and is located in the intron
immediately 59 to the first coding exon of the major AFF3
transcript. The FRA2A-associated repeat is polymorphic in the
general population. Repeat primed PCR showed all individuals
with an expansion of over 300 repeat units expressed FRA2A in
more than 20% of their cells. The expansion was associated with
hypermethylation of a CpG island adjacent to the alternative
promoter and, in at least one case, resulted in transcriptional
silencing of AFF3. These results are consistent with the epigenetic
effects that have been described in other FSFS. Within each of the
three families studied here higher levels of methylation correlate
well with neurodevelopmental delay, higher repeat size and
silencing of AFF3. However, there are striking disparities in the
absolute levels of methylation observed between the families. For
example individuals AII.3 and AII.4 both have .300 repeats and
had evidence of neurodevelopmental delay during childhood but
have lower levels of methylation than BI.2 (,120 repeats, biallelic
expression of AFF3) and C1.2 (106 repeats) neither of whom
showed evidence of developmental delay. A likely explanation for
this is that the assay used here was performed on peripheral blood-
derived cells whereas the phenotype in which we are interested is
developmental and neural. Many developmental loci appear to
show tissue specific differences in DNA methylation [36]. In this
regard the ability to model brain development using cerebral
organoids from patient-derived pluripotent cells [37] may enable
more interpretable transcriptional and epigenomic analyses of the
consequences of CGG-repeat expansion on AFF3.
Nonetheless, all individuals for whom a significant methylation
frequency was measured, show an expanded allele in the pre- or
full mutation range. Repeat sizes of .300 do correlate with
neurodevelopmental effects and expression of the fragile site in a
significant percentage of cells. Carriers of an expanded allele in the
premutation range are phenotypically normal but may show lower
levels of expression of the fragile site.
Table 1. Sizing the repeat in all available family members with gene specific repeat primed PCR.
Family A Family B Family C
I.1 II.3 II.4* III.1 I.2 II.1 I.1 I.2 II.1
allele 1 8 8 8 18 15 8 5 17 8
allele 2 8 .300 .300 .300 6120 .300 8 106 .300
Alleles were sized by gene specific repeat primed PCR. As expansions containing over 300 repeated units cannot be reliably sized using this technique, we indicated
these alleles as ‘‘.300’’. Subject A.II.4 is marked with an asterisk as she is mosaic for a 134-bp deletion taking away the entire CGG repeat in combination with a largely
expanded allele, and this in addition to a normal sized allele.
doi:10.1371/journal.pgen.1004242.t001
AFF3 Silencing in FRA2A
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In one individual (AII.4) a mosaic deletion of 134-bp removed
the entire CGG repeat and the CpG island on the deleted allele
remains unmethylated (data not shown). A similar combination of
a full mutation with an expanded repeat and a deletion
encompassing the repeat has been reported in several fragile X
syndrome patients and recently also in a myotonic dystrophy type
1 case [38,39]. In the fragile X syndrome, the phenotype of
deletion cases is often indistinguishable from that of carriers of an
expanded repeat, a reported exception being an unaffected
individual where the deletion is the major allele present, and the
transcription and translation start sites are preserved [40].
AFF3 belongs to a family of nuclear transcription activating
factors including AFF1/AF4, AFF2/FMR2 and AFF4/AF5q31
[33,41,42]. These proteins form super elongating complexes (SEC)
Figure 5. AFF3 protein-domain and gene structure. A. diagrammatic representation of the AFF3 protein, showing the N-terminal homology
domain (NHD), C-terminal homology domain (CTHD) and two predicted nuclear localisation signals. The 18 amino acids encoded by the alternatively
spliced exon 4 are represented as an ‘‘insertion’’ at position 18 of isoform 1. The 6-bp in-frame deletion we identified in exon 14 of subjects AI.1 and
AII.4, removing two amino acids (position 619 and 621 respectively) is indicated in red. This deletion was predicted to be benign. B. Genomic
structure of AFF3 with the alternately used spliced exon 4 shown in red with asterisk. AFF3 exons 2, 3 and the alternate first exon are not separately
resolvable at this resolution but shown in detail in panel C. Transcription left to right is shown in blue, right to left in brown. CAGE tag defined
transcription start sites are shown aligned with annotated gene structure (blue forward strand transcription, brown reverse strand transcription
shown with negative counts). Y-axis values show average tags per million (TPM) from CAGE libraries from the indicated tissue groups. C. Finer details
of the AFF3 TSS regions are shown along with histograms of human fetal brain RNA-seq read coverage; three replicates are coloured separately.
Splicing of the intron between the alternate first exon and exon 3 (blue asterisk) was supported by 9 independent RNA-seq reads and found in all
three replicates. The CGG repeat and abnormally methylated region (AMR) are shown in red and green respectively, The major transcription start sites
are shown as black arrowed lines. There is no supporting evidence for the RefSeq TSS represented by the pink arrowed line in our data. D. Alignment
of human CGG repeat region and associated TSS with the orthologous mouse region. Nucleotides are color coded (A= green, G = yellow, C = blue,
T = red, alignment gaps are grey). Orange histograms show the predicted G-quadruplex forming potential of the human and mouse sequences. Outer
histograms show CAGE tag 59 ends at single nucleotide resolution in both human (top) and mouse (bottom). TPM counts shown are the average from
brain derived CAGE libraries in each species and represent the precise location of transcription initiations.
doi:10.1371/journal.pgen.1004242.g005
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with active P-TEFb (positive transcription elongation factor) and
AF9/ENL. SECs regulate the induction and expression of
different subsets of genes. AFF3 is the closest paralog of AFF2,
and is 36% identical on the amino acid sequence level. They share
functional domains including the N-terminal Homology Domain
(NHD), the C-terminal Homology Domain (CTHD) involved in
intranuclear localization and binding of G-quadruplex RNA
structures, and the ALF domain that promotes protein degrada-
tion through the proteasome pathway and the transactivation
domain (TAD). Intriguingly, the highly conserved intron 2 TSS
sequences and to a lesser extent the CGG repeat itself, are
predicted to have a strong propensity to form G-quadruplex
Figure 6. Site and stage specific expression of Aff3 in mouse embryos. A. photomicrograph of a lateral view of a 12.5 dpc embryo with the
blue staining representing the gene expression of Aff3. The only area of strong expression at this stage is in the hand plate. B. show a false coloured
but unthresholded image of the brightfield optical projection tomography (OPT) scan of a 11.5 dpc embryo with digital sagittal and coronal sections
from the same embryo shown in C and D. Strong expression is seen in the somites, upper limb bud, the fusing primary palate and the diencephalon
and prosomere1 regions of the developing brain.
doi:10.1371/journal.pgen.1004242.g006
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structures (Figure 5D, orange bars) with the most downstream of
these being present in the 59 UTR of the produced transcript.
Given that AFF3 is known to bind G-quadruplexes, there is the
potential for AFF3 autoregulation at this promoter. Both AFF2 and
AFF3 localize to nuclear speckles and modulate splicing efficiency
[43]. The expression pattern of murine Aff3 overlaps to a
considerable extent with that of murine Aff2 [43,44].
FRAXE is associated with loss of expression of AFF2 through
dynamic repeat expansion of a CGG repeat in the 59 UTR.
FRAXE causes an X-linked non-syndromic intellectual disability
[45]. AFF2 may play an important role in learning, memory,
and language-learning processes [46]. Moreover, rare missense
variations in the highly evolutionary conserved sites of the AFF2
gene might be associated with autism spectrum disorder [47]. The
Aff2 knockout mouse model shows specific cognitive deficits,
including an impaired conditioned fear memory over longer
periods and enhanced long-term potentiation in the hippocampus
[48,49]. Aff3 expression is upregulated in cortical neurons during
the initial steps of cortical differentiation and is downregulated in
postnatal cortex, indicating its involvement in brain development
[44]. We have shown that Aff3 shows strong regional expression in
the developing mouse brain.
AFF3 is thus a reasonable candidate for the neurodevelopmental
features seen in FRA2A carriers in our families. Our data predict
Table 2. Pyrosequencing reliably quantified the methylation of four consecutive CpG dinucleotides per individual
(chr2:100721843–100721885; hg19).
CGCAA CGGAGAGCAGGTC CGGGTGGAAGAGGTTTCCTCCG CGC
Family A
I.1 561,6 461,3 560,5 – 260,5
II.3 1862,0 1763,8 2063,4 – 1462,6
II.4 2462,9 2162,9 2463,8 – 1862,5
III.1 2662,7 2261,5 2563,0 – 2161,1
Family B
I.2 2763,1 2663,1 2863,6 – 2263,1
II.1 4560,4 4463,2 4862,4 – 3362,4
Family C
I.1 561,7 361,3 361,7 – 262,8
I.2 4063,6 4064,4 3464,3 – 3563,6
II.1 5464,5 5262,8 6063,5 – 4563,4
A fifth CpG site is preceded by a 7 base pair T stretch (after bisulfite conversion), making it impossible to assess the exact percentage of cytosines compared to thymines
for that particular site due to the limitations of the pyrosequencing technique. For each individual at least three separate analysis of different bisulfite conversions were
performed. Average methylation percentages and confidence intervals are presented in this table. Methylation cut-off value was set at 10% according to the
manufacturers guidelines.
doi:10.1371/journal.pgen.1004242.t002
Figure 7. Analysis of rs4851214 which maps to coding exon 14 of AFF3 using paired genomic DNA and cDNA templates from the
unaffected carrier mother BI.2 and the affected carrier son BII.1 from family B. A: Both BI.2 and BII.1 are heterozygous for SNP rs4851214 in
genomic DNA as T and C peaks are visible at this site. B: Analysis of cDNA from subject BII.1, shows that only the C allele could be detected in this
patient, indicating monoallelic expression, while in cDNA of subject BI.2 the heterozygous T/C signal was observed, indicating transcription of both
alleles.
doi:10.1371/journal.pgen.1004242.g007
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that FRA2A carriers are haploinsufficient for AFF3, at least in a
subset of tissues. A confident assignment of causality to the
association of AFF3-associated repeat expansion mutations with
neurodevelopmental anomalies is confounded by the rarity of the
fragile site and the strong bias in clinical ascertainment. It is,
however, intriguing that delay in motor and language develop-
ment appears to be a common feature in the individuals presented
here and this may represent a true delay in development rather
than a fixed disability. AFF3 deficiency may then be involved in
the speed of skill acquisition without impairing the developmental
capacity.
A de novo microdeletion of 500 kb on chromosome 2q11.2
removing only AFF3 [50] has been reported in a girl with a severe
multisystem disorder consisting of a mesomelic skeletal dysplasia
(fibular agenesis, abnormal and triangular tibiae, short neck),
urogenital tract malformations, delayed psychomotor development
and recurrent apnoea leading to respiratory arrest at the age of 4
months. This clinical presentation is clearly very different to those
associated with FRA2A but would be consistent with the
expression pattern we demonstrate in mouse embryos. The
clinical differences may be explained by the fact that the
methylation of the repeat and thus the inactivation of the AFF3
gene presumably takes place several weeks after fertilization, so
that development during the first weeks is not affected [51]. It is
also plausible that the transcriptional silencing associated with
FRA2A may by tissue specific given that the alternative promoter
that is immediately adjacent to the expansion mutation shows
evolutionarily-conserved tissue-specific activity, and appears to be
the main driver of AFF3/Aff3 transcription in the brain in humans
and mouse.
Both rare and common fragile sites often co-localize with
evolutionary breakpoints as was postulated previously by Ruiz-
Herrera et al. [52,53]. We have shown through FISH and
BLAST-analysis that the region close to the AFF3 repeat is indeed
involved in a chromosomal rearrangement including a duplication
and inversion of a 24 kb sequence from 2q13 to 2q11.2 followed
by an ancestral head-to–head chromosomal fusion that led at 2q13
that led to the formation of human chromosome 2. The 2q11.2
breakpoint of this rearrangement falls within base pairs of the
repeat and is also present in other primates. The 2q13 region also
co-localizes with FRA2B, an as yet to be characterized rare fragile
site of the same type.
In conclusion, we report a CGG repeat expansion mutation as
the molecular cause of the fragile site FRA2A. FRA2A expression
is associated with methylation of an AFF3 promoter and apparent
transcriptional silencing of AFF3. It is currently difficult to
unequivocally link FRA2A to a specific neurodevelopmental
phenotype but it is plausible that haploinsufficiency for AFF3 in
the developing brain is related to a true developmental delay and
possibly mild intellectual disability.
Materials and Methods
Ethics statement
The ethics committees of the participating study centers
approved the study protocol and all participants gave their written
informed consent. The study was in accordance with the principles
of the current version of the Declaration of Helsinki. The fetal
brain tissue was collected with informed written consent and
ethical approval by Southampton and South West Hants LREC.
The fetal tissue was obtained following surgical termination of
pregnancy and staged according to the Carnegie Classification
[54,55].
Family description: Clinical diagnosis and chromosome
analysis
Family A. The proband (AII.4, Figure 1) was originally
investigated at the age of 7.5-years for mild to moderate learning
disability and enuresis. She was born at term following an
uneventful pregnancy. There were no neonatal problems but her
early motor and language development was reported to be slow.
Her general health was good and her weight was on the 25th
centile for her age. She attended a school for children with special
educational needs. When last seen at the age of 20-years she was
healthy and was working as a checkout operative in a high-street
store and had no evidence of a significant functional neurocog-
nitive deficit. Her elder sister (AII.3) had been investigated several
years earlier for moderate global learning disability and had
attended the same a school for children with special educational
needs. Again she displayed no evidence of significant cognitive
impairment when seen at the age of 26-years. Indeed she was very
much valued in the workplace for remembering numerical codes
for almost the entire stock inventory. AII.3 has a healthy daughter
(AIII.1), born after an uneventful pregnancy. Evaluation of AIII.1
Table 3. Clinical findings in FRA2A carriers.
Family A A A B C
Individual II.3 II.4 III.1 II.1 II.1
Sex Female Female Female Male Female
Age at last assessment (yrs) 33 31 0,2 12 13
Growth Normal Normal Normal Normal Normal
Delayed motor development + + ? + +
Delayed speech and language development + + ? + +
Intellectual disability 2 2 ? Moderate Mild
Required special educational support + + ? + 2
General health Good Good Good Reasonable Reasonable
Other features anal fissure macrocephaly, prematurity, hyperreflexia
FRA2A expression in peripheral blood
lymphocytes
26% 40% 31% 40% 26%
doi:10.1371/journal.pgen.1004242.t003
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at the age of 3 weeks revealed no phenotypic abnormality. No
intellectual problems were apparent in any other relatives of the
three-generation family tree. DNA analysis of the FRAXA locus
was normal and permission to use the remaining peripheral blood
DNA for research purposes was obtained from patient AII.4
(Figure 1). An Epstein-Barr-transformed lymphoblastoid cell line
was established at ECACC (Cambridge, UK) from a peripheral
blood sample of proband AII.4. The index patient showed FRA2A
expression in 40% of the examined cells. At the age of 20-years,
chromosome analysis was repeated and confirmed FRA2A
expression, this time in 21% of the examined cells. Subjects
AII.3 and AIII.1 expressed the fragile site FRA2A in respectively
26% and 31% of the examined cells. The unaffected father
(subject AI.1) showed FRA2A expression in 4% of his cells,
whereas in two unaffected siblings and the mother no indications
were found for FRA2A expression (Figure 1).
Family B. The proband (II.1, Figure 1) was born at 39 weeks
after an uneventful pregnancy. He was the third child of a non-
consanguineous Caucasian couple. There were no problems in the
neonatal period. At 8 weeks of age, an anal fistula was diagnosed
and required three surgical procedures between 5 and 8 months
for cure. He developed mild asthma at 10 months of age. Food
allergies were demonstrated at 12 months of age and were
managed by dietary modification. His height and head circum-
ference were within the normal range, but his development was
slow. He had mild dysmorphic features, including telecanthus,
slightly short palpebral fissures, smooth philtrum, thin upper lip
and a small mouth. Psychological assessment at the age of 12 using
the WISC-IV showed a full-scale IQ in the range 40–52 (,0.1
centile), within the moderate range of intellectual disability. The
Vineland Adaptive Behaviour Scales 11 gave an Adaptive
Behaviour Composite in the range 55–67, below the first centile
and in the low range. His parents and two elder brothers had
normal intelligence and were not dysmorphic. Routine chromo-
somes, subtelomere FISH of chromosomes, molecular testing for
fragile X syndrome and urinary amino acids/organic acids/
mucopolysaccharides gave normal results. The proband expressed
the fragile site FRA2A in 40% of the examined cells. Fragile site
expression was not examined in the other family members.
Family C. The proband (II.1, see Figure 1) was born at 33
weeks after an uneventful pregnancy. She had respiratory distress
syndrome and was treated with surfactant and ventilated for five
days. There were no significant complications in the neonatal
period. Her early development was delayed and she suffered from
intermittent asthma and required ventilator tubes for serious otitis
media. At three years of age, she was seen because of speech delay
– her expressive language was estimated to be at the 2 year level
while receptive language and general development were assessed
at the 2.5–3.0 year level. She was noted to be macrocephalic,
hypotonic and hyperreflexic. Height was normal. At 13 years she is
in an age appropriate class in high school and undertakes all
subjects, except mathematics, with her peers, but struggles to keep
up. She has poor concentration, is easily distractible and does not
like changes in routine or to immediate expectations. She is doing
well socially. The following investigations gave normal results: CT
brain scan, urine amino acids and organic acids, chromosomes,
creatine kinase and thyroid function tests. The proband showed
FRA2A expression in 26% of the examined cells. Fragile site
expression was not examined in the other family members.
Fluorescent in situ hybridisation (FISH) mapping
Peripheral blood lymphocyte-derived metaphase chromosome
preparations from individual AII.3 were obtained using standard
methods. An AFF3-containing BAC-clone from the RPCI library,
RP11-549H5 (AC092667), and clones mapping centromeric
(RP11-436F6, AC010736) and telomeric (RP11-506F3,
AC074387) to AFF3 were obtained from the BACPAC Resource
Center (Oakland, California, USA). Long Range-PCR (LR-PCR)
was used to generate probes of 10 kb and 18 kb situated
respectively immediately 59 and 39 to the promoter region of
AFF3. The following primer pairs were used: L10K (forward 59-
TGCAGGAATGAATGAAGGGCAAGCAA-39 and reverse 59-
TGGCCTCTGGGTGTCGACTTCAAACT-39) and L18K (for-
ward 59-ACAGTTTGGCTTGACCGGGAGGGTTT-39 and
reverse 59- TCAAAAATGTTCCCTTGCCCACAGTGC-39).
LR-PCR was performed using the Expand Long Template
PCR System (Roche, Basel, Switzerland) according to the
manufacturer’s instructions. The amount of BAC DNA used
per reaction was 5–10 ng. All probes were labelled with
digoxigenin-11-dUTP or biotin-16-dUTP (Roche, Indianapolis,
IN) by nick translation. DNA hybridisation and antibody
detection were carried out as described previously [56]. At least
five metaphases were analysed for each hybridisation, using a
Zeiss Axioplan 2 fluorescence microscope equipped with a triple
band-pass filter (#83000 for DAPI, FITC and Texas Red;
Chroma Technology, Brattleboro, VT). Images were collected
using a cooled CCD camera (Princeton Instruments Pentamax,
Roper Scientific, Trenton, NJ) and analysed using IPLab software
(Scanalytics, Vienna, VA).
PCR amplification and hybridization of the FRA2A-
associated CGG repeat
PCR amplification of the normal FRA2A CGG repeat was
performed with the aid of 2.56 PCR Enhancer solution
(Invitrogen, Carlsbad, CA, USA) using a forward primer P1 (59-
GGCCGTAAAAGCCACGAGAGAGGG-39) and a reverse
primer P2 (59-CTTGCGCGCAGGCACACTCAAGAG-39) de-
rived from the sequences flanking the repeat. PCR products were
sequenced and subsequently analysed by use of an ABI Prism 3130
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
A Southern blot was created by digesting 10 mg of DNA,
extracted from blood or Epstein-Barr-virus transformed cells, with
the restriction enzymes HindIII and NcoI (Fermentas GmbH, St.
Leon-Rot, Germany) in separate reactions. The digested DNA was
then separated by electrophoresis on a 0.7% agarose gel. No
ethidium bromide was added during this electrophoresis step to
avoid product-related smearing on the gel that would cause
overestimation of the mosaicism of repeat sizes [57]. After
subsequent denaturation and neutralisation the DNA fragments
were transferred to Hybond N+ membranes. Hybridisation was
performed at 65uC using a specific 32P-labeled 992 bp PCR probe
(forward primer 59- AGCCTTTGTTCCTGGGAATGCT-
GTCTCAAT -39 and reverse primer 59- GGAAAGGCAGGT-
GATCAGCTAGAAGGGTG -39).
Repeat primed PCR was performed to interrogate the number
of CGG repeats in the AFF3 gene with Asuragens CGG Repeat
Primed PCR system designed for detection of Fragile X expanded
alleles. Triplet repeat primed PCR (TP-PCR) uses a locus-specific
forward primer that flanks the repeat. The reverse PCR primer of
the primer pair is designed to hybridise within the CGG repeat
region as it contains a (GCC)5 tail. This generates amplicons of
various sizes as the reverse primers bind to multiple locations
during TP-PCR. As the number of CGG repeats increases, a
characteristic ladder profile appears on the fluorescence electro-
pherogram enabling the rapid and inexpensive identification of
expanded repeats that may have been missed using current PCR
methods. Samples were PCR-amplified by preparing a master
mix containing 11.45 ml of GC-rich AMP buffer, 0.25 ml of
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FAM-labelled AFF3 forward primer (59-GGCCGTAAAAGC-
CACGAGAGAGGG-39), 0.25 ml of AFF3 reverse primer (59-
CTTGCGCGCAGGCACACTCAAGAG-39), 0.5 ml of CGG
primer (59- TACGCATCCCAGTTTGAGACGGCCGCCG-
CCGCCGCC-39), 0.5 ml of nuclease-free water, and 0.05 ml of
GC-rich polymerase mix from Asuragen (Austin, TX). 2 ml of the
DNA sample, typically at 20 ng/ml, was added before transferring
the plate to a thermal cycler (9700, Applied Biosystems, Foster
City, CA). Samples were amplified with an initial heat denatur-
ation step of 95uC for 5 minutes, followed by 10 cycles of 97uC for
35 seconds, 62uC for 35 seconds, and 68uC for 4 minutes, and
then 20 cycles of 97uC for 35 seconds, 62uC for 35 seconds, and
68uC for 4 minutes with a 20 second autoextension at each cycle.
The final extension step was 72uC for 10 minutes. After PCR, 2 ml
of the PCR product was added to a mix with 11 ml HDF and 2 ml
Rox 1000 standard. After a brief denaturation step, samples were
analysed using the ABI Prism 3130 Genetic Analyzer.
Methylation analysis of the AFF3 promoter
The methylation status of the AFF3 associated CGG repeat and
the surrounding region, was analysed by bisulfite sequencing.
Genomic DNA collected from lymphoblastoid cell lines and saliva
(subject AIII.1) was bisulfite-treated using the EpiTect Bisulfite Kit
(Qiagen, Venlo, Netherlands) according to manufacturer’s guide-
lines. Bisulfite treatment converts all non-methylated cytosines into
thymines, while methylated cytosines remain unchanged. Primers
specific for the methylated bisulfite converted DNA (forward 59-
GGTGAGAAATAAAAAGAAAGGAG -39 and reverse 59- CCT-
CAACAACCCTAAAATACC -39) were designed. After PCR
amplification, the CGG surrounding area (chr2:100721494–
100721911; hg19) was sequenced using an ABI Prism 3130
DNA sequencer. Moreover we have performed pyrosequencing
using the AFF3_002 PyroMark CpG assay according to manu-
facturer’s instructions (Qiagen, Venlo, Netherlands) and analysed
the results on a PyroMark Q24. Methylation cut-off value was set
at 10%.
Gene-expression analysis
The expression pattern of AFF3 in human tissues was studied
using a multiple-tissue Northern blot (FirstChoice Northern
Human Blot I, Ambion, Austin, TX, USA). The specific AFF3
probe was a 655-bp PCR product [forward primer 59-TATC-
GAGTGTGGAAATGCAA-39 and reverse primer 59-TGA-
GGTCCCTATGACAGGTG-39] and radiolabelled by the addi-
tion of 32P-dATP and 32P-dCTP (MP, Irvine, California, USA).
Hybridisation was performed according to the manufacturer’s
instructions.
Total RNA-sequencing data from the Illumina Human Body
Map 2.0 project (GSE30611) was obtained from the NCBI Gene
Expression Omnibus. Data from brain (ERR030882, female, 77y),
ovary (ERR030874, female, 47yj) and lymph node (ERR030878,
female, 86y) was downloaded in the form of 2650 bp reads and
imported into CLC genomics workbench v6.01. Transcriptomics
analysis was performed within CLC Genomics using the human
reference genome version hg19. Default settings were used, apart
from a smaller expected insert size of 50 bp. Additionally total
RNA was isolated from the human fetal brain tissues (FB1 54
gestational days (GD), FB2 47 GD, FB3 59 GD) according to the
Trizol (Invitrogen) protocol. The preparation of amplicon libraries
and RNA-Seq analysis were performed following standard
Illumina TruSeq protocols and reads of length 50 bp were
produced on the Illumina GAIIx platform. The fetal tissue was
obtained following surgical termination of pregnancy and
staged according to the Carnegie Classification [54,55]. CAGE
tag data was obtained from the FANTOM4 consortium as both
pre-defined CAGE tag clusters (http://fantom.gsc.riken.jp/
download/Tables/human/CAGE/promoters/tag_clusters/ and
http://fantom.gsc.riken.jp/4/download/Tables/mouse/CAGE/
promoters/tag_clusters/) and as genome aligned individual tags
(http://fantom.gsc.riken.jp/4/download//Tables/human/CAGE/
mapping/). Coordinates were converted from the hg18 reference
genome assembly to hg19 using LiftOver (http://genome.ucsc.
edu/cgi-bin/hgLiftOver). Statistical analysis was performed R
(http://www.R-project.org/; version 3.0.0).
The AFF3 transcript NM_002285 (http://www.ncbi.nlm.
nih.gov/) was searched for cSNP’s. The cSNP’s in FRA2A
patients were tested by PCR followed by sequencing at the
genomic and at the cDNA level. RNA was isolated from
Epstein-Barr-transformed lymphoblastoid cells using Trizol
(Invitrogen, Carlsbad, CA, USA) and converted to cDNA using
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA,
USA). The following primer sets were used: SNP1 (rs4851214)
in exon 14 (forward primer 59- AGTGATGAAGAGGA-
GAATGAACA -39 and reverse primer 59- ATAG-
GAGGCTTGTGGGGATTA -39) and SNP2 (rs13427251) in
exon 25 (forward primer 59-GTGTGTCTGGTATGTTTA-
CAC-39 and reverse primer 59-GGATCAGCATCTAGTC-
TAAG-39). Sequencing products were analysed on an ABI
3130 Prism automatic sequencer.
The Aff3 riboprobe for whole mount in situ hybridisation to
mouse embryos was generated by in vitro transcription from a PCR
template amplified from the Aff3 39UTR using mouse genomic
DNA as a template. T3 (for sense probe) and T7 (for antisense
probe) binding sites were added to the forward (59-AATTAACCCT-
CACTAAAGGCTCTCCAACCGGATCCAGAAT-39) and reverse
(59-TAATACGACTCACTATAGGAGCCCATGGCACCTCTCT-
39) primers. The WISH protocol and OPT scanning was
performed exactly as previously described [58].
Mutation analysis of the AFF3 gene and marker analysis
All coding exons of the AFF3 gene were PCR amplified at the
genomic level using standard protocols for all patients and relatives
to exclude the presence of any other disease-causing mutation.
PCR products were enzymatically purified and sequenced.
Sequences were analysed with an ABI Prism 3130 DNA
sequencer.
For the marker analysis, genomic DNA was isolated from
peripheral blood from all available family members using standard
procedures. Highly polymorphic microsatellite markers, D2S2209
and D2S2311, were selected from the Marshfield genetic map in
the proximity of the repeat. These markers are both dinucleotides
with an average heterozygosity of 71%. Analysis was performed by
a Go Taq DNA polymerase mediated PCR, with fluorescently
labeled primers. Fragment analysis of amplified products was
performed using an ABI PRISM 3130 XL Genetic Analyzer
(Applied Biosystems). Allele identification was done with Gene
mapper v3.7 software (Applied Biosystems).
Supporting Information
Figure S1 CGG-repeat region in AFF3 intron 2. Sequence of
the CGG-repeat region in intron 2 of the AFF3 gene shown in
telomeric-centrometic orientation. The CGG repeat is shown in
bold blue text. The repeat lies within the 134 bp region that is
deleted in subject AII.4 which is shown in bold black text. Forward
and reverse primers used for the amplification of the CGG repeat
are indicated with blue arrows. The primers used for bisulfite
sequencing (chr2:100721494–100721911; hg19) are indicated with
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orange arrows and CpG sites that were analysed with bisulfite
pyrosequencing are represented in bold orange text.
(TIF)
Figure S2 A: Fragment-length analysis of regular PCR and
TP-PCR generated products of the CGG repeat in the AFF3
gene of family A. Fluorescently-labeled PCR products of all
individuals of family A were separated by capillary electropho-
resis on an ABI PRISM 3130 XL Genetic Analyzer. For every
individual a PCR covering the entire repeat was analyzed in
addition to a repeat primed PCR (Asuragen). Individual AI.1
appeared homozygous for a repeat with 8 units as no fading
repeat-signal is present after repeat-primed PCR (right corner).
For individual AII.4 the 134 bp-deletion of the repeat and
surrounding region is clearly detected in addition to a short 8-
unit repeat. An expanded allele of over 300 units is present in
this individual as shown with repeat primed PCR. This
expanded allele could not be covered by regular PCR covering
the entire repeat. In individuals AII.3 and AIII.1 a normal
range repeat of 8 and 18 repeated units respectively was
detected in addition to an expanded allele containing over 300
units. B: Fragment-length analysis of regular PCR and TP-PCR
generated products of the CGG repeat in the AFF3 gene of
family B. In individual BI.2 one normal range allele with 15
repeated units was identified. In addition, a second slightly
expanded allele of about 120 repeated units was detected by
regular PCR covering the repeat. This expansion was confirmed
with repeat primed PCR. In individual BII.1 a normal range
repeat of 8 was detected in addition to an expanded allele
containing over 300 units. The trace labelled FR_blanco
represents a blanc reference lane. C: Fragment-length analysis
of regular PCR and TP-PCR generated products of the CGG
repeat in the AFF3 gene of family C. The father of family C,
CI.1, is heterozygous for the number of repeated units,
displaying two alleles with respectively 5 and 8 repeated units.
In the mother, CI.2, a second slightly expanded allele with 106
repeated units was detected in addition to a normal range allele
with 17 CGG-units by regular PCR. This expansion was
confirmed with repeat primed PCR. In individual CII.1 a
normal range repeat of 8 was detected in addition to an
expanded allele containing over 300 units. For each individual
of this family the raw analysis data of the genetic analyzer are
displayed in the upper right corner. The trace labelled
FR_blanco represents a blanc reference lane.
(TIF)
Figure S3 Genotyping results of the microsatellite marker
analysis on family A with markers D2S2209 and DS2311. From
the combination of both markers we can conclude that both sisters
(AII.3 and AII.4) have inherited a different allele from their father
(AI.1), while they share a common allele that is probably inherited
from the mother. It is again this allele that was passed on to the
granddaughter (AIII.1). As individuals AII.3, AII.4 and AIII.1 all
carry an expanded and hypermethylated allele for the AFF3
associated repeat, it can be presumed that the expansion was
probably inherited from the mother.
(TIF)
Figure S4 a: Bisulfite sequences of family A. After bisulfite
treatment of the genomic DNA from lymphoblastoid cell lines and
saliva (subject AIII.1) of all available family members, DNA
sequences of the region located at chr2:100721494–100721911;
hg19 were analysed with an ABI Prism 3130 DNA sequencer.
This region covers 50 separate CpG dinucleotides of which nine
are shown in this figure. Methylation patterns were consistent
across all 50 CpG sites for each individual. Blue (C-) peaks at
CpG-sites in addition to a red T-signal indicate the presence of at
least partial methylation. b: Bisulfite sequences of family B. c:
Bisulfite sequences of family C.
(TIF)
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